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ceived anti-thymocyte globulin 30 mg/M2 days -1, 1, 3, and 6.
Engraftment was assessed by whole blood RFLP analysis or XY
FISH (sex mismatched transplants). 30/32 patients, including all 11
haplo-stem cell recipients and all 12 unrelated donor recipients,
engrafted stably. Only transient, incomplete engraftment was seen
in the cord blood recipient and one 5/6 matched recipient. En-
graftment was 90% donor in 19/32 (59%) by day 30 and in 20 of
25 (80%) evaluable patients by day 100. 3/5 patients with subop-
timal engraftment at day 100 had residual circulating CLL cells.
Signiﬁcant renal dysfunction (creatinine 2.5mg/dl) occurred in
15/32 by Day 100 with 2 patients needing dialysis. Renal failure
resolved or abated greatly when tacrolimus was reduced or discon-
tinued. Day 100 transplant related mortality was 3/11 (36%) in
haplo-transplant patients and 1/20 (5%) of URD or 5/6 (low risk)
transplant patients. Acute GVHD (D100) was seen in 21 of 32
patients (66%), but was in general easily managed with steroids,
particularly after low risk transplants. Day 100 transplant related
mortality was 3 of 11 haplo recipients and 1 of 19 low risk patients.
In total 20/32 patients survive at a median 209 days post-trans-
plant. 14 of these 20 patients have been free of progression of
malignancy since transplant and one more has been disease free for
16 months since chemotherapy and donor lymphocyte infusion (ie.
47% currently progression free). Sirolimus added to tacrolimus
and methotrexate appears to facilitate engraftment, minimize graft
versus host disease, and potentially contribute to control of malig-
nant disease.
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PERFORIN, FASL, TNFR1, TWEAK, TRAIL, AND DR3-TL1A ARE NOT
REQUIRED FOR EFFICIENT T CELL MEDIATED RESISTANCE AGAINST
ALLOGENEIC BONE MARROW GRAFTS
Zimmerman, Z.F.1, Jones, A.M.1, Deyev, V.1, Blazar, B.R.2, Yagita,
H.3, Podack, E.R.1, Levy, R.B.1 1. University of Miami School of
Medicine, Miami, FL; 2. University of Minnesota Cancer Center, Mine-
apolis, MN; 3. Juntendo University School of Medicine, Tokyo, Japan.
Immunologic resistance to allogeneic BMT is a major concern in
clinical transplantation, however the molecular pathway(s) medi-
ating this resistance remains unclear. In antigen sensitized CD8
T cell mediated resistance models, mice deﬁcient in perforin and
FasL (B6-cdd), demonstrate efﬁcient rejection of MHC mis-
matched or matched allogeneic BM. Surprisingly, resistance re-
mains intact in the absence of TNFR1 or R2 on donor cells, as well
as in the presence of blocking mAb to TRAIL. This study further
investigates the in vivo effector mechanism(s) in the absence of
these molecules. TWEAK and TL1a are expressed on T cells and
can induce apoptosis when bound to their receptors Fn14 and DR3
respectively. To sensitively examine their role in resistance, block-
ing mAb’s against these ligands were applied with the simultaneous
disruption of perforin, FAS-L, TNF, and TRAIL function. B6-cdd
mice (H-2b) were primed 3 weeks prior to 9.0Gy TBI and trans-
plant with 107 BALB/c (H-2d) TNFR1
/
 or C3H.SW (H-2b)
BM-TCD to assess both MHC mismatched and matched alloge-
neic resistance models. On day 0 and 1 post-BMT, recipients
received 250 ug of -TRAIL (N2B2) and -TWEAK (MTW-1)
mAb. In the MiHA disparate model, mice additionally received
-TL1a mAb (L466) or a control non-blocking mAb to
TL1a(L3A10). Early presence (Day 5) of both multi-potential
CFU-HPP and lineage committed CFU-IL3 progenitor popula-
tions was assessed in recipient spleens. Syngeneic control recipients
exhibited signiﬁcant CFU numbers. In contrast, low or absent
numbers of both CFU progenitor populations were detected in
allogeneic transplants lacking perforin, FasL, and TNFR1. Nota-
bly, mice additionally receiving -TWEAK, TRAIL, and TL1a
also exhibited effective resistance. Therefore, resistance remained
intact despite the simultaneous disruption of these six candidate
effector pathways. These ﬁndings highlight the question, what
precisely, is the role of apoptosis in allogeneic BMT rejection and
also raise the possibility for the involvement of other molecular
players distinct from death inducing ligands. In the MHC disparate
model, marrow from allogeneic B6 bim
/
 donors (kind gift of Dr.
A. Strasser) was effectively rejected in BALB/c recipients. These
observations indicate that if the intrinsic apoptotic pathway is
required for primed T cell resistance against allogeneic progeni-
tors, it is not engaged by Bim. Further studies are in progress to
delineate the contribution of these pathways.
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ACTIVATED ALLOGENEIC NK CELLS AS SUPPRESSORS OF HOST ALLO-
REACTIVE RESPONSES
Liu, H., Welniak, L.A., Murphy, W.J. Universtiy of Nevada, Reno,
Reno, NV.
Nonmyeloablative conditioning regimens offer promise in low-
ering toxicity and extending the applicability of bone marrow
transplantation (BMT). However, despite many means of host
immunosuppression, marrow rejection by host effector cells re-
mains a signiﬁcant concern. As NK cells have been shown to be
potent immunoregulatory cells both in vitro and in vivo, we studied
the ability of activated donor NK cells to speciﬁcally suppress or
delete host reactive immune cells, thereby facilitating engraftment
of donor marrow. We initially tested this hypothesis in vitro.
Activated H2d ALAK (adherent lymphokine activated killer, IL-2
activated T cell depleted bone marrow and spleen cells,98% NK
cells) cells from BALB/c mice signiﬁcantly suppressed the prolif-
eration of H2b splenocytes from C57BL/6 (B6) mice in mixed
lymphocyte responses (MLR) stimulated with irradiated H2d
splenocytes from BALB/c mice (p  0.01). The ability for H2b
splenocytes to kill H2d tumor targets was also signiﬁcantly inhib-
ited by activated H2d ALAK cells (p  0.01). The same number of
H2b ALAK cells or H2d splenocytes did not show the same sup-
pressive effect. Interestingly, in a secondary MLR using an alloge-
neic B6 (H2b) spleen T cell line (stimulated by irradiated BALB/c
splenocytes), activated H2d ALAK cells also greatly suppressed the
activity of the B6 T cells killing H2d tumor targets. These results
suggest that activated H2d ALAK cells can speciﬁcally suppress the
anti-H2d activity of the H2b splenocytes in both primary and
secondary responses. Anti-TGF antibody blockade did not di-
minish this suppressive effect of ALAK cells, suggesting that this
activity was not dependent on TGF secretion. We are currently
testing these ﬁndings in vivo using a nonmyeloablative BMT
model. These in vitro studies suggest that activated donor NK cells
provide a promising way to promote donor engraftment without
involving systemic and nonspeciﬁc suppression of the immune
system.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THE TREAT-
MENT OF FANCONI ANEMIA USING A FLUDARABINE-BASED CYTORE-
DUCTIVE REGIMEN AND T-CELL DEPLETED GRAFTS FROM ALTERNA-
TIVE DONORS
Boulad, F.1, Auerbach, A.D.2, Kolb, A.1, Small, T.N.1, Prasad, V.1,
Prockop, S.1, Torok-Castanza, J.1, Casson, A.1, Collins, N.H.1, Kernan,
N.A.1, O’Reilly, R.J.1 1. Memorial Sloan-Kettering Cancer Center,
New York, NY; 2. Rockefeller University, New York, NY.
Table. Total Donor Splenic CFU% of Controls
Recipient
(n > 3)
Donor
(107 Bone
Marrow
TCD)
mAb Administered
(D0, D  1)
CFU-
IL3%
Control
CFU-
HPP %
Control
B6-cdd B6 gfp none 100% 100%
B6-cdd
BALB/c
TNFR1/ none <1% <1%
B6-cdd TNFR1/ TRAIL  TWEAK <1% <1%
B6-cdd C3H.SW none <3% <5%
B6-cdd C3H.SW TRAIL  TWEAK <1% <5%
B6-cdd C3H.SW
TRAIL  TWEAK 
TL1a(control) <8% <3%
B6-cdd C3H.SW
TRAIL  TWEAK 
TL1a <7% <1%
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